{"paper_id":"ccaddef3-dca9-40ad-8c73-590a90a326a5","body_text":"Abstract\nEndometriosis diagnosis is often limited by the resolution of conventional imaging techniques (ultrasound/non-targeted MRI) as well as the invasiveness and recurrence risks associated with laparoscopy. To overcome these challenges, we developed anti-MMP-9 peptide-conjugated NaGdF4@PEG-Cy5.5 nanoparticles (NPPCNs), which integrate NaGdF4 cores to enhance T1 relaxivity and biocompatibility for MMP-9-targeted molecular imaging. In vitro studies confirmed both cytocompatibility and high-affinity MMP-9 binding. In vivo biodistribution, assessed through T1-weighted MRI and fluorescence imaging within 48 h post-injection, revealed significant nanoparticle accumulation in endometriotic lesions, with elevated signal intensity compared to controls. This MMP-9-targeted theranostic platform offers a non-invasive method for lesion detection, providing a novel approach for precise diagnosis and surgical navigation in endometriosis.\nSimilar content being viewed by others\nData Availability\nThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.\nReferences\n(2010) Practice bulletin no. 114: management of endometriosis. Obstet Gynecol 116:223–236. https://doi.org/10.1097/AOG.0b013e3181e8b073\nAdamson GD, Kennedy S, Hummelshoj L (2010) Creating solutions in endometriosis: global collaboration through the World Endometriosis Research Foundation. J Endometr 2:3–6. https://doi.org/10.1177/228402651000200102\nZhang M, Wang X, Xia X et al (2022) Endometrial epithelial cells-derived exosomes deliver microRNA-30c to block the BCL9/Wnt/CD44 signaling and inhibit cell invasion and migration in ovarian endometriosis. Cell Death Discov 8:151. https://doi.org/10.1038/s41420-022-00941-6\nMissmer SA, Hankinson SE, Spiegelman D et al (2004) Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol 160:784–796. https://doi.org/10.1093/aje/kwh275\nOhashi N, Aoki R, Shinozaki S et al (2011) A case of anemia with schistocytosis, thrombocytopenia, and acute renal failure caused by adenomyosis. Intern Med 50:2347–2350. https://doi.org/10.2169/internalmedicine.50.5628\nSon J, Lee DW, Seong EY et al (2010) Acute kidney injury due to menstruation-related disseminated intravascular coagulation in an adenomyosis patient: a case report. J Korean Med Sci 25:1372–1374. https://doi.org/10.3346/jkms.2010.25.9.1372\nKrálíčková M, Laganà AS, Ghezzi F, Vetvicka V (2020) Endometriosis and risk of ovarian cancer: what do we know? Arch Gynecol Obstet 301:1–10. https://doi.org/10.1007/s00404-019-05358-8\nKvaskoff M, Mahamat-Saleh Y, Farland LV et al (2021) Endometriosis and cancer: a systematic review and meta-analysis. Hum Reprod Update 27:393–420. https://doi.org/10.1093/humupd/dmaa045\nGiudice LC, Kao LC (2004) Endometriosis. Lancet 364:1789–1799. https://doi.org/10.1016/S0140-6736(04)17403-5\nFrayne J, Milroy T, Simonis M, Lam A (2023) Challenges in diagnosing and managing endometriosis in general practice: a Western Australian qualitative study. Aust J Gen Pract 52:547–555. https://doi.org/10.31128/AJGP-10-22-6579\nDe Corte P, Klinghardt M, von Stockum S, Heinemann K (2025) Time to diagnose endometriosis: current status, challenges and regional characteristics-a systematic literature review. BJOG 132:118–130. https://doi.org/10.1111/1471-0528.17973\nShafrir AL, Farland LV, Shah DK et al (2018) Risk for and consequences of endometriosis: a critical epidemiologic review. Best Pract Res Clin Obstet Gynaecol 51:1–15. https://doi.org/10.1016/j.bpobgyn.2018.06.001\nMedeiros LR, Rosa MI, Silva BR et al (2015) Accuracy of magnetic resonance in deeply infiltrating endometriosis: a systematic review and meta-analysis. Arch Gynecol Obstet 291:611–621. https://doi.org/10.1007/s00404-014-3470-7\nIto TE, Abi Khalil ED, Taffel M, Moawad GN (2017) Magnetic resonance imaging correlation to intraoperative findings of deeply infiltrative endometriosis. Fertil Steril 107:e11–e12. https://doi.org/10.1016/j.fertnstert.2016.10.024\nGeraldes CFGC (2024) Manganese oxide nanoparticles for MRI-based multimodal imaging and theranostics. Molecules 29:5591. https://doi.org/10.3390/molecules29235591\nLiu C, Gao Z, Zeng J et al (2013) Magnetic/upconversion fluorescent NaGdF4:Yb,Er nanoparticle-based dual-modal molecular probes for imaging tiny tumors in vivo. ACS Nano 7:7227–7240. https://doi.org/10.1021/nn4030898\nOliveira H, Bednarkiewicz A, Falk A et al (2019) Critical considerations on the clinical translation of upconversion nanoparticles (UCNPs): recommendations from the European Upconversion Network (COST Action CM1403). Adv Healthc Mater 8:e1801233. https://doi.org/10.1002/adhm.201801233\nLiu Z, Yao C, Ni H et al (2025) Fluorescence imaging of MALAT1 expression using a Cy5.5-labeled antisense oligonucleotide in lung cancer and epidermal carcinoma cells. Cancer Imaging 25:82. https://doi.org/10.1186/s40644-025-00903-y\nCao X-C, Mao X-L, Lu S-S et al (2024) A PD-L1-targeted probe Cy5.5-A11 for in vivo imaging of multiple tumors. ACS Omega 9:43826–43833. https://doi.org/10.1021/acsomega.4c06761\nMihara M, Hara H, Araki J et al (2012) Indocyanine green (ICG) lymphography is superior to lymphoscintigraphy for diagnostic imaging of early lymphedema of the upper limbs. PLoS One 7:e38182. https://doi.org/10.1371/journal.pone.0038182\nWu Q, Pan W, Wu G et al (2023) CD40-targeting magnetic nanoparticles for MRI/optical dual-modality molecular imaging of vulnerable atherosclerotic plaques. Atherosclerosis 369:17–26. https://doi.org/10.1016/j.atherosclerosis.2023.02.008\nCollette T, Bellehumeur C, Kats R et al (2004) Evidence for an increased release of proteolytic activity by the eutopic endometrial tissue in women with endometriosis and for involvement of matrix metalloproteinase-9. Hum Reprod 19:1257–1264. https://doi.org/10.1093/humrep/deh290\nKoivunen E, Arap W, Valtanen H et al (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17:768–774. https://doi.org/10.1038/11703\nWu S, Chu X, Lv G et al (2025) Mesenchymal stem cells with polydopamine-coated NaGdF4 nanoparticles with Ca2+ chelation ability for ischemic stroke therapy. Adv Mater 37:2416020. https://doi.org/10.1002/adma.202416020\nZhang H, Wu Y, Wang J et al (2018) In vivo MR imaging of glioma recruitment of adoptive T-cells labeled with NaGdF4 -TAT nanoprobes. Small. https://doi.org/10.1002/smll.201702951\nXing H, Zhang S, Bu W et al (2014) Ultrasmall NaGdF4 nanodots for efficient MR angiography and atherosclerotic plaque imaging. Adv Mater 26:3867–3872. https://doi.org/10.1002/adma.201305222\nErogbogbo F, Chang C-W, May JL et al (2012) Bioconjugation of luminescent silicon quantum dots to gadolinium ions for bioimaging applications. Nanoscale 4:5483–5489. https://doi.org/10.1039/c2nr31002c\nWu S, Xu T, Gao J et al (2024) Non-invasive diagnosis of liver fibrosis via MRI using targeted gadolinium-based nanoparticles. Eur J Nucl Med Mol Imaging 52:48–61. https://doi.org/10.1007/s00259-024-06894-5\nDamasco JA, Ohulchanskyy TY, Mahajan S et al (2021) Excretable, ultrasmall hexagonal NaGdF4:Yb50% nanoparticles for bimodal imaging and radiosensitization. Cancer Nanotechnol 12:4. https://doi.org/10.1186/s12645-021-00075-x\nNi D, Jiang D, Im H-J et al (2018) Radiolabeled polyoxometalate clusters: kidney dysfunction evaluation and tumor diagnosis by positron emission tomography imaging. Biomaterials 171:144–152. https://doi.org/10.1016/j.biomaterials.2018.04.019\nMaeda H, Wu J, Sawa T et al (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284. https://doi.org/10.1016/s0168-3659(99)00248-5\nKe J, Ye J, Li M, Zhu Z (2021) The role of matrix metalloproteinases in endometriosis: a potential target. Biomolecules 11:1739. https://doi.org/10.3390/biom11111739\nFriend DR (2017) Drug delivery for the treatment of endometriosis and uterine fibroids. Drug Deliv Transl Res 7:829–839. https://doi.org/10.1007/s13346-017-0423-2\nZhu S, Zhang J, Xue N et al (2023) Highly specific neutrophil-mediated delivery of albumin nanoparticles to ectopic lesion for endometriosis therapy. J Nanobiotechnology 21:81. https://doi.org/10.1186/s12951-023-01831-4\nZhang Q, Wu S, Li Y et al (2023) Endometriosis-targeted MRI imaging using bevacizumab-modified nanoparticles aimed at vascular endothelial growth factor. Nanoscale Adv 5:3994–4001. https://doi.org/10.1039/d2na00787h\nAcknowledgements\nThis work was supported by Shanghai Municipal Health Commission (Grant No.20224Y0382), Huashan Hospital, Fudan University (Grant No.200201, Grant No.046), National Natural Science Fund for Young Scientists Program C (No.82502300) and 2023 SKY Imaging Research Fund of the Chinese International Medical Foundation (z-2014-07-2301).\nAuthor information\nAuthors and Affiliations\nContributions\nQi Zhang, Haicheng Li and Linghui Xu contributed equally to this work. Qi Zhang and Haicheng Li designed the experiments, performed data analysis, and drafted the manuscript. Linghui Xu, Shiman Wu, Yujia Shen, Yiting Wang, Xiongrui Guo, and Qianwen Zhu conducted the experimental work and data collection. Xiaohong Ruan and Junhai Zhang supervised the study, provided critical revisions, and secured funding. All authors reviewed and approved the final manuscript.\nCorresponding authors\nEthics declarations\nEthical Approval\nThis study was performed in line with the principles of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Jiangmen Hospital and the Animal (2025185A) Ethics Committee of Fudan University (202308001S). A waiver of informed consent was formally granted for this retrospective analysis in accordance with institutional ethical regulations and national guidelines for non-interventional studies.\nConflict of Interest\nThe authors have no relevant financial or non-financial interests to disclose.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nSupplementary Information\nBelow is the link to the electronic supplementary material.\nRights and permissions\nSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.\nAbout this article\nCite this article\nZhang, Q., Li, H., Xu, L. et al. Engineering Anti-MMP-9 Peptide-Modified Nanoparticles for Precision MRI Diagnosis of Endometriosis. Mol Imaging Biol 28, 334–346 (2026). https://doi.org/10.1007/s11307-026-02086-9\nReceived:\nRevised:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s11307-026-02086-9","source_license":"public-domain-us","license_restricted":false}